COMP <GO>
ETON vs JNJ // PIOTROSKI F-SCORE QUALITY
Eton Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ETON 2
— JNJ 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $53.67 (+3.61%) • MKT CAP: $1.53B
piotroski-score
7/9
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ETON | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 67.90% | -14.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.90% | 25.50% | -26.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.66% | 2.97% | -2.31 | JNJ | /fcf-yield <GO> |
| Operating Margin | -1.10% | 34.70% | -35.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -5.80% | 28.50% | -34.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 104.90% | 6.00% | +98.90 | ETON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.37 | 5.59 | +7.78 | ETON | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.8 | 62.1 | -9.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.53B | $662.49B | -$660.96B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ETON REV | JNJ REV | ETON GROSS % | JNJ GROSS % | ETON FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $80.0M | $94.19B | 53.5% | 67.9% | $10.2M | $19.70B |
| FY 2024 | $39.0M | $88.82B | 60.0% | 69.1% | $943.0K | $19.84B |
| FY 2023 | $31.6M | $85.16B | — | — | $6.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
JNJ // BETA 1.08